Literature DB >> 26597208

Complement system activation in ANCA vasculitis: A translational success story?

Cees G M Kallenberg1, Peter Heeringa2.   

Abstract

The ANCA-associated vasculitides (AAV) are characterized by pauci-immune necrotizing small to medium size vessel vasculitis frequently including necrotizing crescentric glomerulonephritis. Neutrophil activation by ANCA appears a primary pathogenic event. More recently, the complement system has been shown to be involved as well. Activation of the alternative pathway of complement, at least in part via activated neutrophils, results, amongst others, in the generation of C5a, a strong chemoattractant for neutrophils. C5a is also effective in neutrophil priming, a process leading to surface expression of the ANCA antigens so enabling neutrophils to be further activated by ANCA. Both in vitro and in vivo experimental data and histopathological studies from AAV patients underscore the role of complement, and particularly of C5a, in the pathophysiology of AAV. Preliminary data show that blocking of the C5a-receptor is a promising approach in the treatment of AAV.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ANCA-associated vasculitis; C5a; complement

Mesh:

Substances:

Year:  2015        PMID: 26597208     DOI: 10.1016/j.molimm.2015.06.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

Review 1.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

Review 2.  Novel Therapies for ANCA-associated Vasculitis.

Authors:  Sara Monti; Fabio Brandolino; Alessandra Milanesi; Blerina Xoxi; Paolo Delvino; Carlomaurizio Montecucco
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

3.  Gene Expression Pathways across Multiple Tissues in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Reveal Core Pathways of Disease Pathology.

Authors:  Marcia A Friedman; Dongseok Choi; Stephen R Planck; James T Rosenbaum; Cailin H Sibley
Journal:  J Rheumatol       Date:  2019-01-15       Impact factor: 4.666

Review 4.  Neutrophils as emerging therapeutic targets.

Authors:  Tamás Németh; Markus Sperandio; Attila Mócsai
Journal:  Nat Rev Drug Discov       Date:  2020-01-22       Impact factor: 84.694

5.  A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis.

Authors:  Jianling Tao; Jonathan Lieberman; Richard A Lafayette; Neeraja Kambham
Journal:  BMC Nephrol       Date:  2018-12-12       Impact factor: 2.388

6.  Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation.

Authors:  Ingrid Lopatko Fagerström; Anne-Lie Ståhl; Maria Mossberg; Ramesh Tati; Ann-Charlotte Kristoffersson; Robin Kahn; Jean-Loup Bascands; Julie Klein; Joost P Schanstra; Mårten Segelmark; Diana Karpman
Journal:  EBioMedicine       Date:  2019-08-20       Impact factor: 8.143

7.  The confused puzzles in antineutrophil cytoplasmic antibody-associated vasculitis activity evaluation: A case report.

Authors:  Ai-Hua Zhang; Wei-Long Yao; Wen-Hu Liu
Journal:  Clin Case Rep       Date:  2021-07-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.